Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed

Permanent URI for this communityhttps://hdl.handle.net/11727/4806

Browse

Filters

2019 - 20203

Settings

Type: search.filters.itemtype.ReviewSubject: search.filters.subject.heart failure

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    EuroEcho 2019: highlights
    (2020) Magne, Julien; Bharucha, Tara; Cikes, Maya; Galderisi, Maurizio; Price, Suzanna; Sade, Leyla Elif; Popescu, Bogdan A.; Cosyns, Bernard; Edvardsen, Thor; 32182333
    The annual meeting of the European Association of Cardiovascular Imaging, EuroEcho 2019, was held in Vienna, Austria, in December 2019. In this article, we present a summary of the 'Highlights' session.
  • No Thumbnail Available
    Item
    The year 2019 in the European Heart Journal - Cardiovascular Imaging: part II
    (2020) Cosyns, Bernard; Haugaa, Kristina H.; Gerber, Bernrhard; Gimelli, Alessia; Sade, Leyla Elif; Maurer, Gerald; Popescu, Bogdan A.; Edvardsen, Thor; 33188688
    The European Heart Journal - Cardiovascular Imaging was Launched in 2012 and has during these years become one of the leading multimodality cardiovascular imaging journal. The journal is now established as one of the top cardiovascular journals and is the most important cardiovascular imaging journal in Europe. The most important studies published in our Journal from 2019 will be highlighted in two reports. Part II will focus on valvular heart disease, heart failure, cardiomyopathies, and congenital heart disease. While Part I of the review has focused on studies about myocardial function and risk prediction, myocardial ischaemia, and emerging techniques in cardiovascular imaging.
  • No Thumbnail Available
    Item
    Natriuretic Peptides in Clinical Practice
    (2019) Cavusoglu, Yüksel; Alper, Ahmet Taha; Altay, Hakan; Celik, Ahmet; Demirkan, Burcu; Guvenc, Tolga Sinan; Kucukoglu, Mehmet Serdar; Nalbantgil, Sanem; Ozdemir, Murat; Ozin, Bulent; Sayin, Tamer; Yildirimturk, Ozlem; Yilmaz, Mehmet Birhan; Zorkun, Cafer; 30860204; AAE-1392-2021; AAD-9938-2021
    Natriuretic peptides have long been introduced into clinical practice. These biomarkers have certainly been shown to provide useful information in the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy. Although, there are some limitations in using of these markers such as lack of specificity, aging, renal dysfunction or obesity, among the huge number of candidates for heart failure biomarkers, only natriuretic peptides are currently widely used in daily clinical practice in heart failure. Recent heart failure guidelines recognize natriuretic peptides as an essential tool in the new diagnostic and therapeutic algorithms. Furthermore, natriuretic peptides are not only used in the diagnosis or prognosis of heart failure, but also these biomarkers are referred to have some potential role in primary prevention, cardio-oncology, advanced heart failure, assessment of response to cardiac resynchronization therapy, pulmonary arterial hypertension, acute coronary syndromes, atrial fibrillation and valvular heart disease. In this article, natriuretic peptides have been reviewed for their updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of various clinical conditions have been addressed in the form of expert opinion based on the available data in the literature.